Equity Real Estate Investment Trusts (REITs)

Janus Living

Janus Living released FY2025 Q1 earnings on May 6, 2026 (EST), actual revenue USD 148.93M, actual EPS USD 0

Janus Living released FY2026 Q1 earnings on May 6 After-Market (EST), actual revenue USD 200.35 M (forecast USD 191.8 M), actual EPS USD -0.05 (forecast USD 0.0619)

Janus Living to Release FY2026 Q1 Earnings on May 5 After-Market EST, Forecast Revenue USD 191.8 M, EPS USD 0.0619

Janus Living's Stock Price Rises to New High After Positive Ratings by Bank of America Global Research and Others

Janus Living Director Katherine M. Sandstrom Purchases 21,000 A-1 Shares

Janus Living Director John V. Arabia Purchased Company Stocks

Janus Living CEO Scott Brinker Buys 100,000 Shares of A-1 Common Stock

Janus Living COO Buys Company Stocks

Janus Living released FY2024 annual earnings on March 17 (EST), actual revenue USD 568.48 M, actual EPS USD 0

JAN.US released FY2025 Annual Earnings on March 17, 2026 (BJT) with actual revenue of USD 603.99M and EPS of USD 0

Board of Directors approves strategic review of biotech assets

Janone changes company name and stock target

JanOne Inc. Appoints Vay Tham as Chief Revenue Officer and President of ALT5 Sigma, Inc.

JanOne Inc.'s subsidiary ALT5 Sigma witnessed significant trading volume in April and May 2024

JanOne Inc. agrees to acquire ALT 5 Sigma Inc.

Janone Acquires Blockchain Fintech Provider Alt 5 Sigma Inc.

Micware

Silexion Therapeutics

GCL Global

Jupiter Neurosciences

Capstone

BiomX

Wetour Robotics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Arcadia Biosciences

Ordinary dividend (cash)

Ex Date: 2026.06.12 (EST), Cash dividend 0.1599 USD

Earnings Watch

Janus Living | 10-Q: FY2026 Q1 Revenue: USD 4.712 M

Healthpeak Properties (NYSE:DOC) reported Q1 2026 adjusted funds from operations of $0.45 per share, raising its full-year guidance after significant capital moves, including a senior housing IPO and a $100 million stock repurchase. CEO Scott Brinker highlighted strong performance in life sciences and outpatient medical sectors, with net debt to EBITDA at 5.4 times. The IPO of Janus Living is expected to be neutral in 2026 but accretive thereafter. The outpatient medical segment showed robust leasing activity, achieving 5.4% cash re-leasing spreads and 91% occupancy. Life science occupancy improved to 77.7%.

Market Beat

Healthpeak Properties

iShares US Real Estate ETF

iShares US Healthcare Providers

SPDR Dow Jones Global Real Estate ETF

VanEck Biotech ETF

iShares Residential and Multisector Real Estate ETF

Invesco Biotechnology & Genome ETF

Schw Us Reit

Direxion S&P Biotech Bull 3X

SPDR S&P Health

iShares Biotechnology ETF

Vanguard Real Estate ETF

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

VG Health

FlexShares Glbl Quality Real Estate ETF

Direxion S&P Biotech Bear 3X

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

iShares Global REIT

SPDR Dow Jones REIT ETF

Real Est Select Spdr

WisdomTree New Economy Real Estate Fund

Blackstone

HCA Healthcare

Healthpeak Properties Q1 Earnings Call Highlights

Healthpeak Properties, Inc. has raised its 2026 earnings guidance following the successful IPO of Janus Living, Inc., which generated approximately $880 million in net proceeds. For Q1 2026, Healthpeak reported a net income of $0.28 per share and Nareit FFO of $0.42 per share. The company also highlighted significant growth in outpatient medical and lab lease executions, alongside a recapitalization generating $267 million. Healthpeak's ownership in Janus Living stands at 81.6%, with the latter's market cap at $6.9 billion. The company continues to focus on sustainability and corporate impact initiatives.

fidelity

S&P Global

Healthpeak Properties Raises 2026 Earnings Guidance Following Completion of the Janus Living IPO, Accretive Capital Allocation, and Strong First Quarter 2026 Results

JAN's quiet period will end on April 29th, following its IPO where it issued 42 million shares for $840 million. During this period, underwriters and insiders were restricted from issuing research reports. Post-quiet period, several brokerages, including Bank of America and Royal Bank of Canada, have initiated coverage with positive ratings and price targets ranging from $27 to $29. The stock is currently trading at $24.65, down 2.1%, with a market cap of $6.33 billion. Insider buying has been noted, with significant purchases by the CEO and a director.

Bank of America

ROYAL BANK OF CANADA

Wells Fargo

Bank of Nova Scottia

BNP Paribas

Fermi

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

JAN's Quiet Period To Expire  on April 29th (NYSE:JAN)

Shares of JAN (NYSE:JAN) have received an average "Buy" rating from seven analysts, with a twelve-month price target averaging $27.14. Recent coverage includes upgrades and target prices from various brokerages, with KeyCorp and Morgan Stanley setting targets at $28.00. Insider purchases have increased significantly, with directors acquiring a total of 187,000 shares valued at $3.74 million in the last quarter. The stock opened at $24.00, with a market cap of $6.16 billion and a P/E ratio of -62.29, indicating potential volatility.

KeyCorp

Barclays

Morgan Stanley

MarketWise

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

JAN (NYSE:JAN) Receives Consensus Recommendation of "Buy" from Analysts

SNDK

FSLY

Top Wall Street analysts have initiated coverage on several companies with bullish ratings. Evercore ISI's Amit Daryanani rated SanDisk Corp (SNDK) as Outperform with a price target of $1,200. Morgan Stanley's Ronald Kamdem rated Janus Living Inc (JAN) Overweight with a target of $28. Piper Sandler's Matt O’Brien rated Adagio Medical Holdings Inc (ADGM) Overweight with a target of $3. Raymond James' Martin Auster rated Spyre Therapeutics Inc (SYRE) Strong Buy with a target of $80. Evercore's Peter Levine rated Fastly Inc (FSLY) Outperform with a target of $32.

- Top Wall Street analysts have recently altered their outlooks on several stocks.  
- Analyst Amit Daryanani rates SanDisk Corp (SNDK) as Outperform with a target of $1,200, while Ronald Kamdem gives Janus Living Inc (JAN) an Overweight rating of $28.  
- Other analysts have shared similar views on Adagio Medical Holdings Inc (ADGM) and Spyre Therapeutics Inc (SYRE), with respective target prices of $3 and $80.

benzinga_article

Sandisk

Fastly

Adagio Medical

Spyre Therapeutics

SPDR S&P Health Equip

iShares Semiconductor ETF

First Trust Nasdaq Food & Semicon

Direxion Semicon Bull 3X

Invesco PHLX Semiconductor ETF

SPDR S&P Semicon

Invesco Semiconductors ETF

VanEck Semiconductor ETF

iShares US Medical Devices

Evercore

Piper Sandler Cos

Raymond James Financial

Sandisk - WI

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

This SanDisk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Janus Living | 10-K: FY2025 Revenue: USD 24.84 M

Janus Living(JAN.US)